

The somatotrophic axis in postmenopausal women during six month of transdermal continuous 17 β -estradiol administration combined with oral medroxyprogesterone

Zmiany aktywności osi somatotropowej w trakcie sześciomiesięcznej przezskórnej podaży 17 β -estradiolu wraz z doustną podażą medroksyprogesteronu u kobiet po menopauzie

Milewicz Tomasz¹, Krzysiek Józef¹, Rogatko Iwona², Sztefko Krystyna², Stochmal Ewa³, Hubalewska-Dydejczyk Alicja³, Jach Robert⁴, Radowski Stanisław⁵

¹ Klinika Endokrynologii Ginekologicznej Collegium Medicum Uniwersytetu Jagiellońskiego w Krakowie, Polska

² Zakład Biochemii Klinicznej Uniwersyteckiego Szpitala Dziecięcego w Krakowie, Polska

³ Katedra i Klinika Endokrynologii Collegium Medicum Uniwersytetu Jagiellońskiego w Krakowie, Polska

⁴ Katedra Ginekologii i Położnictwa Collegium Medicum Uniwersytetu Jagiellońskiego w Krakowie, Polska

⁵ Klinika Endokrynologii Ginekologicznej Akademii Medycznej w Warszawie, Polska

Abstract

Aim: The evaluation of the influence of continuous transdermal estradiol supplementation combined with oral medroxyprogesterone on the somatotrophic axis in postmenopausal women.

Material and methods: 25 women completed the study. Group A – 13 women received transdermal 17 β -estradiol (Oesclim 50 - Fournier-Solvay) combined with oral 5 mg daily medroxyprogesterone (Gestomikron - Adamed). Group B - 12 women without treatment. Basic plasma FSH, estradiol, glucose, insulin, SHBG, hGH, total and free IGF-I, IGFBP-1 as well as IGFBP-3 were measured initially and at the 12th and 24th week of the study.

Results: The mean plasma FSH level was reduced and mean plasma estradiol level was increased in group A during estradiol supplementation. Mean plasma level of free IGF-I and free to total IGF-I ratio were increased in group A during 24 weeks of hormone therapy. In the control group (group B) there was the significant increase in mean plasma IGFBP-3 level. Other parameters showed no significant changes in the control group.

Conclusion: The administration of transdermal 17 β -estradiol combined with oral medroxyprogesterone increases the IGF-I bioavailability. However this influence do not exceed the physiological level of IGF-I bioavailability.

Key words: **estradiol / medroxyprogesterone actate / hGH / IGF-I / IGFBP-3 / postmenopause /**

Adres do korespondencji:

Tomasz Milewicz

Klinika Endokrynologii Ginekologicznej, Collegium Medicum Uniwersytetu Jagiellońskiego,

ul. Kopernika 23, 31-501 Kraków, Polska

tel./fax: +48 12 424 85 60

e-mail: milewicz@interia.eu

Otrzymano: 16.06.2010

Zaakceptowano do druku: 30.03.2011

Streszczenie

Cel pracy: Celem pracy była ocena wpływu łącznej podaży 17 β -estradiolu przezskórnie wraz z doustną podażą octanu medroksyprogesteronu na stężenia hormonów osi somatotropowej u kobiet po menopauzie.

Materiał i metody: 25 kobiet wyraziło zgodę i ukończyło badanie. Grupa A - 13 kobiet, które otrzymywały przezskórnie 17 β -estradiol (Oesclim 50 - Fournier-Solvay) wraz z doustną podażą 5 mg octanu medroksyprogesteronu dziennie (Gestomikron - Adamed). Grupa B - 12 kobiet, które nie otrzymywały suplementacji hormonalnej. W chwili rozpoczęcia badania, 12 i 24 tygodniu jego trwania dokonano pomiarów w surowicy w warunkach podstawowych stężeń FSH, estradiolu, glukozy, insuliny, SHBG, hGH, całkowitego i wolnego IGF-I, IGFBP-1 oraz IGFBP-3.

Wyniki: W trakcie stosowania łącznej ciągłej podaży estradiolu i octanu medroksyprogesteronu w grupie A stwierdzono spadek stężenia FSH i wzrost stężenia estradiolu. Po 24 tygodniach suplementacji hormonalnej doszło do wzrostu stężenia w surowicy wolnego IGF-I oraz wskaźnika wolnego do całkowitego IGF-I. W grupie B (kontrolnej) obserwowano istotny statystycznie wzrost stężenia IGFBP-3. Stężenia pozostałych parametrów w tej grupie nie uległy istotnym statystycznie zmianom.

Wniosek: Zastosowanie łącznej podaży przezskórnej 17 β -estradiolu wraz z doustną podażą octanu medroksyprogesteronu doprowadziło do wzrostu biodostępności IGF-I, jednakowoż wzrost ten nie przekroczył stężeń fizjologicznych

Słowa kluczowe: **estradiol / octan medroksyprogesteronu / hGH / IGF-I / IGFBP-3 / postmenopauza /**

Introduction

Circulating insulin-like growth factor-I (IGF-I) is mainly produced by the liver under GH stimulation and is influenced by nutrition and insulin. IGF-I bioavailability is regulated by interactions with specific binding proteins (IGFBPs) [1]. The somatotrophic axis is also affected by hormonal milieu [2, 3]. A number of experiments indicate that sex steroids exert either stimulatory or inhibitory action on the somatotrophic axis [3, 4]. Evidence that estradiol is involved in the regulation of human Growth Hormone (hGH) - Insulin-like Growth Factor-I (IGF-I) - Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) system is provided not only by the observation that mean hGH level is higher in women than men and that the fall in hGH as well as IGF-I levels with aging is correlated with estradiol level but also by the fact that estradiol has a direct effect on IGF-I synthesis and release independent of hGH. Estradiol plays also a permissive role in pituitary hGH release [5-7]. The latter role of estradiol is based in its influence on both pituitary increase in IGF-I mRNA as well as on regulation of pituitary somatostatin concentration [8,9]. Estrogens and IGF-I have synergistic effect on cell proliferation [10]. IGF-I augments the function of estrogen receptor [10]. Total IGF-I serum level correlated directly to free sex hormones and inversely to SHBG level in postmenopausal women [11]. Gunter et al conducted a case cohort study of relation between free IGF-I and endometrial cancer based on data from Women Health Initiative Study and found an inverse association between plasma level of free IGF-I and endometrial carcinoma [12]. In another study of the same group of WHI postmenopausal women they found a positive association between endogenous estradiol level, free IGF-I and risk of colorectal cancer in postmenopausal women [13].

IGF-I is also regarded as auto/paracrine mediator of estradiol action [14]. Estradiol exerts different effects on serum IGF-I levels depending on its origin, route of administration and dose [2]. Different kinds of hormone therapy (HT) have different effect on the IGF-I system, depending on route of administration,

oestrogen dose, basal IGF-I values and type of progestin [1]. Oral estrogens due to their hepatocellular effect decrease the liver IGF-I synthesis and therefore reduces its circulating level [10]. The reduced level increases mean diurnal serum GH level through reduced feedback inhibition [15]. The progestins endowed with androgenic effects-the 19-nortestosterone derivatives and, to a lesser extent, medroxyprogesterone acetate (MPA)-tend to reverse the IGF-I decrease induced by oral oestrogens [1, 16]. There are conflicting reports on the effect of transdermal 17 β -estradiol administration on the plasma level of total and free IGF-I. Cardim et al, Stomati et al and Bellantoni et al found no effect of transdermal estradiol therapy on the plasma levels of total and free IGF-I as well as IGFBP-1 [17-19]. Weissberger et al applied transdermal 0.1 mg/24 hours estradiol patches and restored estradiol plasma level to midfollicular one [15]. That resulted in increase of serum total IGF-I level. However, neither oral nor transdermal estrogen administration completely reverses the age related reductions in spontaneous or GHRH-stimulated GH and IGF-I secretion [19].

IGFBP-3 plasma level was higher in postmenopausal women compared to premenopausal ones. This lowers the bioavailability of IGF-I in older females [20]. Oral estrogen administration causes a two to three-fold increase in IGFBP-1 levels and reduction in IGFBP-3 levels. Androgenic progestins oppose the IGFBP-1 increase as well as IGFBP-3 decrease induced by oral oestrogens [1, 16, 17]. The transdermal estradiol administration reduced the plasma level of IGFBP-3 in postmenopausal women older than 62 years of age [19].

In circulation most of IGF-I binds to IGFBP-3, that inhibits the action of IGF-I. The remaining free IGF-I can cross the endothelial barrier and interact with receptors. That is why measuring free IGF-I is more useful than assessment of total IGF-I in evaluation of proliferative influence of IGF-I on neoplastic lesions [21]. Data on the effect of estrogen therapy (ET) and different progestins on the level of free IGF-I are scant and inconsistent [1].

Aim

Therefore it seems interesting to evaluate the influence of continuous transdermal estradiol supplementation combined with oral medroxyprogesterone on the somatotrophic axis in postmenopausal women.

Material and methods

The study protocol was approved by the Jagiellonian University Ethical Board. Thirty four postmenopausal (having plasma FSH >30U/l and 17 β -estradiol <50ng/l) were recruited for the study and gave the informed consent to participate. None of them had received any form of HT prior to the beginning of the study. Of 34 postmenopausal women assigned to both groups (A and the control group) the study was completed by 25 participants (mean age 51.4 \pm 6.5 years) (13 in group A and 12 in group B). The women with diabetes mellitus, thyroid diseases and adrenal glands' disorders as well as with contraindication to hormone replacement therapy were excluded by careful history taking and physical examination and evaluating the glucose fasting level, thyroid hormones, pap smear, mammography and plasma cortisol. Each woman became postmenopausal after 45 years of age. The women were randomly assigned to one of the study groups. Women of group A (N=13) were treated with transdermal supplementation of 17 β -estradiol (Oesclim 50, Fournier-Solvay) at a dose of 0.05 mg/24 hours combined with oral medroxyprogesterone acetate at a daily dose of 5 mg (Gestomikron - Adamed) as a continuous therapy. Group B (N=12) consisted of women who did not receive HT treatment (control group). The patients were examined before the treatment and twice during the period of 24 weeks of HT in 12 weeks intervals. During each visit, special attention was paid to physical and psychological well-being of each patient, as well as to the characteristic menopausal symptoms. Clinical characteristics of the study groups is presented in table I.

The basal, fasting plasma total insulin-like growth factor-I (IGF-I), free IGF-I, insulin-like growth factor binding protein-1 and 3 (IGFBP-1, IGFBP-3), human growth hormone (hGH) glucose, insulin, estradiol, follicle stimulating hormone (FSH) and sex hormone binding globuline (SHBG) levels were measured before the treatment (examination I) and after 12 weeks (examination II) and 24 weeks (examination III) of HT. At the same time intervals, all the parameters were measured in the control group. All sample tubes were kept and transported in the ice box, than centrifuged as soon as possible at 4°C (refrigerated centrifuge, Heraeus, Germany). Plasma was stored frozen at -70°C until the determination of the hormones, not later than after 3 months of storage. Frozen samples were thawed slowly only once and incubated for 30 minutes at 4°C prior the analysis. Plasma glucose level was determined on the day of blood sampling. Plasma glucose was measured by the enzymatic method (Vitros dry chemistry analyzer, Johnson and Johnson). Plasma hormone levels were measured by using commercial Abbot MEIA kits (sensitivity: 1ng/ml for estradiol cross reactivity with LH, TSH, hCG 0.039%; sensitivity for FSH 0.5mIU/ml interference 5% with bilirubin and hemoglobin, cross reactivity with hCG 0.016%). IGF-I plasma level was measured by RIA Biosource Europe kits (sensitivity 0.25ng/ml; intersample and interkit variability was 4.1% and 9.3% resp.; cross reactivity with insulin, hGH and IGF-II 0.001%, 0.01% and 0.2% resp.).

Free IGF-I plasma levels were measured by means of DRG USA ELISA kits with sensitivity of 0.015ng/ml and no cross reactivity with free IGF-II, insulin, IGFBP-1, IGFBP-3. IGFBP-1 and IGFBP-3 plasma levels were measured by RIA kits (Diagnostic System Laboratories, USA). Sensitivity for both ones was 0.5ng/ml and specificity was 100% for IGFBP-1 and 99% for IGFBP-3.

Descriptive statistics, including mean values, median and SE, were calculated for all studied variables. The data obtained in two visits / groups were compared by means of Welch's t-test of equality of expected values and F-test of equality of variances. Significance level was set at $p < 0.05$. Statistical calculations were performed using Statistica 3.1 software.

Results

At the beginning of the study there were no statistically significant differences between group A and B. (Table I).

Table I. The initial, clinical characteristics of patients with normal glucose metabolism who received transdermal 17 β -estradiol supplementation combined with oral medroxyprogesterone (group A) and control group without treatment (group B).

Parametr	Group A n=13	Group B n=12	p
Age [lat]	51.4 \pm 7.8	47.1 \pm 7.8	NS
BMI	23.6 \pm 2.6	24.4 \pm 4.6	NS
WHR	0.78 \pm 0.05	0.8 \pm 0.05	NS
FSH [U/l]	111.8 \pm 38.9	98.0 \pm 31.3	NS
Estradiol [ng/l]	12.2 \pm 11.5	14.1 \pm 7.9	NS
SHBG [mg/l]	54.0 \pm 36.7	50.4 \pm 27.9	NS
Glucose fasting [mmol/l]	4.8 \pm 0.7	4.7 \pm 0.6	NS
Insulin fasting [mU/l]	5.7 \pm 2.3	6.7 \pm 2.0	NS

The administration of continuous transdermal 17 β -estradiol combined with oral medroxyprogesterone reduced the mean FSH level and increased mean estradiol level already after 12 weeks. This change remained for the next 12 weeks. No such changes were seen in the control group. (Table II). Mean plasma level of free IGF-I increased after 12 weeks of HT. The increased level of free IGF-I remained for the next 12 weeks of treatment. This change increased also the free/total IGF-I ratio after 12 weeks of HT. The ratio dropped after next 12 weeks but still was higher than the initial value ($p < 0.05$). The mean plasma levels of IGFBP-3, IGFBP-1 and total IGF-I as well as the IGFBP-3/IGF-I ratio were not influenced by the HT. However in the control group the increase in the mean plasma level of IGFBP-3 was found after 24 weeks of observation. (Table III).

Discussion

Our study showed that continuous transdermal administration of 17 β -estradiol combined with oral medroxyprogesterone increased the free IGF-I plasma level and showed no influence on mean plasma levels of total IGF-I and IGFBP-1.

Table II. The influence of transdermal 17 β -estradiol supplementation combined with oral medroxyprogesterone (group A) on parameters of clinical characteristics compared to the influence of 6 months' observation of the control group in patients with normal glucose metabolism.

Parametr	Prior to HT	GROUP n = 13	A	p	Initial visit	GROUP B n = 12	(controls)	p
		3 rd month of HT	6 th month of HT			3 rd month	6 th month	
BMI	23.6 \pm 2.6	24.7 \pm 3.6	25.2 \pm 3.5	NS	24.4 \pm 4.6	24.6 \pm 4.3	24.9 \pm 5.0	NS
WHR	0.78 \pm 0.05	0.79 \pm 0.05	0.80 \pm 0.05	NS	0.80 \pm 0.05	0.80 \pm 0.06	0.80 \pm 0.08	NS
FSH [U/l]	111.8 \pm 38.9	76.8 \pm 32.8	73.0 \pm 36.4	<0.05	98.0 \pm 31.3	83.6 \pm 20.9	101.2 \pm 51.3	NS
Estradiol [ng/l]	12.2 \pm 11.5	40.7 \pm 34.9	52.2 \pm 50.4	<0.05	14.1 \pm 7.9	18.8 \pm 8.1	18.5 \pm 7.7	NS
Fasting glucose [mmol/l]	4.8 \pm 0.7	4.7 \pm 0.7	5.0 \pm 0.6	NS	4.7 \pm 1.1	4.9 \pm 0.9	4.8 \pm 0.5	NS
Fasting insulin [mU/l]	5.7 \pm 2.3	6.2 \pm 2.2	9.1 \pm 5.4	NS	6.7 \pm 2.0	6.0 \pm 3.2	8.4 \pm 2.7	NS
SHBG [mg/l]	50.8 \pm 32.6	42.9 \pm 23.7	48.9 \pm 36.1	NS	50.4 \pm 27.9	82.8 \pm 80.4	65.7 \pm 65.4	NS

Table III. The influence of transdermal 17 β -estradiol supplementation combined with oral medroxyprogesterone (group A) on parameters of hGH-IGF-I-IGFBP axis compared to the influence of 6 months' observation of the control group in patients with normal glucose metabolism.

Parametr	Prior to HT	GROUP n = 13	A	p	Initial visit	GROUP B n = 12	(controls)	p
		3 rd month of HT	6 th month of HT			3 rd month	6 th month	
hGH (mg/l)	3.1 \pm 2.3	2.8 \pm 2.4	2.1 \pm 1.3	NS	2.7 \pm 2.6	3.6 \pm 3.5	5.9 \pm 5.8	NS
IGF-I total (ug/l)	214.9 \pm 60.9	168.4 \pm 67.9	276.8 \pm 166.2	<0.05	203.1 \pm 41.9	222.4 \pm 59.4	232.6 \pm 80.7	NS
free IGF-I (ug/l)	2.2 \pm 1.6	5.3 \pm 2.2	6.1 \pm 2.4	<0.001	3.6 \pm 3.0	5.1 \pm 4.6	4.1 \pm 2.3	NS
IGFBP-3 (mg/l)	4.3 \pm 1.3	4.4 \pm 0.5	4.5 \pm 0.8	NS	3.8 \pm 0.5	4.5 \pm 0.4	4.9 \pm 1.0	<0.005
IGFBP-1 (ug/l)	36.6 \pm 15.5	29.6 \pm 17.2	37.9 \pm 21.0	NS	36.9 \pm 13.9	48.4 \pm 23.5	43.2 \pm 21.9	NS
free/total IGF-I [%]	1.0 \pm 1.0	3.6 \pm 1.8	2.0 \pm 1.0	<0.05	2.0 \pm 1.0	2.5 \pm 1.6	3.0 \pm 2.0	NS
IGFBP-3/IGF-I [%]	2.14 \pm 0.9	2.6 \pm 1.0	2.1 \pm 0.5	NS	1.8 \pm 0.6	2.2 \pm 0.7	2.6 \pm 1.5	NS

The hormone therapy prevented the increase in plasma level of IGFBP-3. However it should be mentioned that the limited number of patients included into the study reduces the strength of the conclusion. Stomati et al found no statistically significant change of plasma level of total IGF-I level during transdermal 17 β -estradiol administration combined with oral medroxyprogesterone [18]. Stanosz et al in their recent study of 75 postmenopausal women with osteopenia found the increase in total IGF-I after 12 weeks of transdermal estradiol therapy combined with progesterone given to subgroup of 25 women [22]. Bellantoni et al applied the transdermal estradiol supplementation with 100 μ g patches for 6 weeks and also found no influence on plasma IGF-I levels [19]. However the therapy reduced the IGFBP-3 plasma level [19]. Weissberger et al used the same therapy as Bellantoni group but observed the increase in mean total IGF-I level [15]. Similar results were obtained by Słowinska-Szrednicka et al [23]. Our results seem similar to those obtained by Cardim et al [17]. They found the increase in plasma level of free IGF-I and no influence on the plasma total IGF-I and IGFBP-1 levels during six cycles of transdermal

estradiol administration with norethisterone acetate [17]. Helle et al compared plasma levels of IGF-I, free IGF-I, IGF binding proteins -1 and -3 in 114 postmenopausal and 39 premenopausal women and found lower levels of total and free IGF-I as well as higher levels of IGFBP-3 in postmenopausal women [20]. That finding may explain the increase in IGFBP-3 during the 24 weeks of observation in group B.

The hormone therapy applied in our study increased the free to total IGF-I ratio from 0.82% \pm 0.41 to 2.0% \pm 0.6. The ratio did not exceed that found by Kawai et al who reported the free/total IGF-I ratio ranging from 0.95 to 2.02% [24]. However Skjaerbaek et al reported lower free/total IGF-I ratio (0.66% \pm 0.05%) than that found by Kawai et al [25].

Conclusion

The continuous transdermal 17 β -estradiol administration combined with oral medroxyprogesterone increased the bioavailability of plasma IGF-I

References:

1. Campagnoli C, Abba C, Ambroggio S, Peris C. Differential effects of progestins on the circulating IGF-I system. *Maturitas*. 2003, 46, 39-44.
2. Blake E, Adel T, Santoro N. Relationships between insulin-like growth hormone factor-1 and estradiol in reproductive aging. *Fertil Steril*. 1997, 67, 697-701.
3. Milewicz T, Krzysiek J, Sztelfo K, [et al.]. 17 β -estradiol regulation of human growth hormone (hGH), insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) axis in hypogonadotropic, hypergonadotropic women. *Pol J Endocrinol*. 2005, 56, 876-882.
4. Caufriez A. The pubertal spurt: effects of sex steroids on growth hormone and insulin-like growth factor I. *Eur J Obstet Gynecol Reprod Biol*. 1997, 71, 215-217.
5. Ho K, O'Sullivan A, Weissberger A, [et al.]. Sex steroid regulation of growth hormone secretion and action. *Horm Res*. 1996, 45, 67-73.
6. Kirchengast S, Hartmann B, Huber J. Serum levels of sex hormones, thyroid hormones, growth hormone, IGF I, and cortisol and their relations to body fat distribution in healthy women dependent on their menopausal status. *Z Morphol Anthropol*. 1996, 81, 223-234.
7. Wilson M. Administration of IGF-I affects the GH axis and adolescent growth in normal monkeys. *J Endocrinol*. 1997, 153, 327-335.
8. Hennessey A, Wilson M, Albers H. Somatostatin mRNA levels within the periventricular nucleus are regulated by estradiol and insulin-like growth factor-I in immature female rats. *Mol Cell Neurosci*. 1994, 5, 540-548.
9. Michels K, Lee W, Seltzer A, [et al.]. Up-regulation of pituitary [125]insulin-like growth factor-I (IGF-I) binding and IGF binding protein-2 and IGF-I gene expression by estrogen. *Endocrinology*. 1993, 132, 23-29.
10. Campagnoli C, Ambroggio S, Biglia N, Sismondi P. Conjugated estrogens and breast cancer risk. *Gynecol Endocrinol*. 1999, 13, 13-19.
11. Bezemer I, Rinaldi S, Dossus L, [et al.]. C-peptide, IGF-I, sex-steroid hormones and adiposity: a cross-sectional study in healthy women within the European Prospective Investigation into Cancer and Nutrition (EPIC). *Cancer Causes Control*. 2005, 16, 561-572.
12. Gunter M, Hoover D, Yu H, [et al.]. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. *Cancer Epidemiol Biomarkers Pre*. 2008, 17, 921-929.
13. Gunter M, Hoover D, Yu H, [et al.]. Insulin, insulin-like growth factor-I, endogenous estradiol and risk of colorectal cancer in postmenopausal women. *Cancer Res*. 2008, 68, 329-337.
14. Rajkumar K., Dheen T., Krsek M, Murphy L. Impaired estrogen action in the uterus of insulin-like growth factor binding protein-1 transgenic mice. *Endocrinology*. 1996, 137, 1258-1264.
15. Weissberger A, Ho K, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. *J Clin Endocrinol Metab*. 1991, 72, 374-381.
16. Heald A, Selby P, White A, Gibson J. Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis. *Am J Obstet Gynecol*. 2000, 183, 593-600.
17. Cardim H, Lopes C, Giannella-Neto D, [et al.]. The insulin-like growth factor-I system and hormone replacement therapy. *Fertil Steril*. 2001, 75, 282-287.
18. Stomati M, Hartmann B, Spinetti A, [et al.]. Effects of hormonal replacement therapy on plasma sex hormone-binding globulin, androgen and insulin-like growth factor-1 levels in postmenopausal women. *J Endocrinol Invest*. 1996, 19, 535-541.
19. Bellantoni M, Vittone J, Campfield A. Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research center study. *J Clin Endocrinol Metab*. 1996, 81, 2848-2853.
20. Helle S, Ekse D, Holly J, [et al.]. The IGF-system in healthy pre- and postmenopausal women: relations to demographic variables and sex-steroids. *J Steroid Biochem Mol Biol*. 2002; 81, 95-102.
21. Li B, Khosravi M, Berkel H, [et al.]. Free insulin-like growth factor-I and breast cancer risk. *Int J Cancer*. 2001, 91, 736-739.
22. Stanosz S, Zochowska E, Safranow K, [et al.]. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia. *Metabolism*. 2009, 58, 1-7.
23. Slowinska-Szednicka J, Zgliczynski S, Jeske W, [et al.]. Transdermal 17 beta-estradiol combined with oral progestogen increases plasma levels of insulin-like growth factor-I in postmenopausal women. *J Endocrinol Invest*. 1992, 15, 533-538.
24. Kawai-N, Kanzaki-S, Takano-Watou S, [et al.]. Serum free insulin-like growth factor I (IGF-I), total IGF-I, and IGF-binding protein-3 concentrations in normal children and children with growth hormone deficiency. *J Clin Endocrinol Metab*. 1999, 84, 82-89.
25. Skjaerbaek C, Vahl N, Frystyk J, [et al.]. Serum free insulin-like growth factor-I in growth hormone-deficient adults before and after growth hormone replacement. *Eur J Endocrinol*. 1997, 137, 132-137.